Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial
Journal
Lancet (London, England)
Journal Volume
369
Journal Issue
9580
Date Issued
2007-06-30
Author(s)
Paavonen, Jorma
Jenkins, David
Bosch, F Xavier
Naud, Paulo
Salmerón, Jorge
Wheeler, Cosette M
Apter, Dan L
Kitchener, Henry C
Castellsague, Xavier
de Carvalho, Newton S
Skinner, S Rachel
Harper, Diane M
Hedrick, James A
Jaisamrarn, Unnop
Limson, Genara Am
Dionne, Marc
Quint, Wim
Spiessens, Bart
Peeters, Pascal
Struyf, Frank
Wieting, Susan L
Lehtinen, Matti O
Dubin, Gary
Abstract
The aim of this interim analysis of a large, international phase III study was to assess the efficacy of an AS04 adjuvanted L1 virus-like-particle prophylactic candidate vaccine against infection with human papillomavirus (HPV) types 16 and 18 in young women.
SDGs
Type
journal article